Aytu BioPharma Appoints Christopher Brooke as Chief Operating Officer

Strategic Insights -

Aytu BioPharma, a biopharmaceutical company, has appointed Christopher Brooke as its new Chief Operating Officer. Brooke brings over 20 years of general management experience in healthcare, having held various roles of increasing responsibility at companies such as AmerisourceBergen, Centocor (Johnson & Johnson), and MedImmune (AstraZeneca). His rare disease experience includes launching pediatric inflammatory bowel disease indications and leading the pediatric infectious disease franchise.

Key Takeaways:

  • Christopher Brooke, with over 20 years of experience in healthcare, has been appointed as Aytu BioPharma's Chief Operating Officer, effective November 14, 2022.
  • Brooke has a rare disease experience in launching pediatric inflammatory bowel disease indications and leading the pediatric infectious disease franchise at Johnson & Johnson and AstraZeneca, respectively.
  • Prior to his appointment, Brooke served as Aytu BioPharma's Executive Vice President, Rare Disease Development since April 2021, and co-founded Rumpus Therapeutics in January 2019 to develop new medicines for pediatric onset rare and orphan diseases.
  • Brooke holds a 47.5% ownership interest in Rumpus, which entered an asset purchase agreement with Aytu BioPharma in April 2021, acquiring commercial global licenses for the development asset enzastaurin (AR101).
  • Aytu BioPharma is required to pay up to $67.5 million in earn-out payments upon achieving certain regulatory and commercial milestones, with two milestones achieved in fiscal 2022 totaling $4.0 million, paid in shares of common stock and cash.

Statistics:

  • $1.5 million: Up-front fee paid by Aytu BioPharma to acquire commercial global licenses for AR101 in April 2021.
  • 47.5%:Christopher Brooke's ownership interest in Rumpus.
  • $67.5 million: Maximum earn-out payments Aytu BioPharma is required to pay upon achieving certain regulatory and commercial milestones.
  • $4.0 million: Total earn-out payments achieved by Aytu BioPharma in fiscal 2022.
  • 2,188,940: Number of shares of Aytu common stock paid as earn-out payment in fiscal 2022.
  • $2.6 million: Cash paid to Rumpus as earn-out payment in fiscal 2022.

Sources:

  • [Securities and Exchange Commission (EDGAR Online via COMTEX)] - Reporting Date: November 15, 2022 (Section 5.02(b))